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Background: Trogocytosis is defined as the transfer of cell-surface membrane proteins and membrane patches from
one cell to another through contact. It is reported that human epidermal growth factor receptor 2 (HER2) could be
transferred from cancer cells to monocytes via trogocytosis; however, the clinical significance of this is unknown. The
aim of this study is to demonstrate the presence and evaluate the clinical significance of HER2+ tumor-infiltrated
immune cells (arising through HER2 trogocytosis) in HER2-overexpressing (HER2+) breast cancer patients receiving
trastuzumab-based primary systemic therapy (PST).
Methods: To assess the trogocytosis of HER2 from cancer cells to immune cells, and to evaluate the up- and
down-regulation of HER2 on immune and cancer cells, peripheral blood mononuclear cells from healthy volunteers and
breast cancer patients were co-cultured with HER2+ and HER2-negative breast cancer cell lines with and without
trastuzumab, respectively. The correlation between HER2 expression on tumor-infiltrated immune cells and a
pathological complete response (pCR) in HER2+ breast cancer patients treated with trastuzumab-based PST was analyzed.
Results: HER2 was transferred from HER2+ breast cancer cells to monocytes and natural killer cells by trogocytosis.
Trastuzumab-mediated trogocytosed-HER2+ effector cells exhibited greater CD107a expression than non-HER2-trogocytosed
effector cells. In breast cancer patients, HER2 expression on tumor-infiltrated immune cells in treatment naïve HER2+ tumors
was associated with a pCR to trastuzumab-based PST.
Conclusions: HER2-trogocytosis is visible evidence of tumor microenvironment interaction between cancer cells and
immune cells. Given that effective contact between these cells is critical for immune destruction of target cancer cells, this
interaction is of great significance. It is possible that HER2 trogocytosis could be used as a predictive biomarker for
trastuzumab-based PST efficacy in HER2+ breast cancer patients.
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Human epidermal growth factor receptor 2 positive
(HER2+) breast cancer cells are recognized by trastuzu-
mab and undergo opsonization, which results in cell
death by antibody-dependent cellular cytotoxicity
(ADCC) in the presence of peripheral blood mono-
nuclear cells (PBMCs). Following cancer cell–immune
cell contact, an immune complex (IC) consisting of
HER2, trastuzumab, and the Fcγreceptor (FcγR) of an ef-
fector cell, such as a natural killer (NK) cell or mono-
cyte, is formed. The IC and small membrane fragments
of the target cell, which surround the IC, are then trans-
ferred to the effector cell, resulting in reduced HER2 ex-
pression on the target cell surface. This phenomenon is
broadly defined as trogocytosis [1], although the original
definition of trogocytosis, as reported by Griffin et al.,
referred to the transfer of IC caps from the surface of
lymphocytes to macrophages. This was mediated by
macrophage Fc receptors [2], and occurred without de-
struction of the lymphocyte.
Although the overexpression and amplification of
HER2 in breast cancer is associated with a poor progno-
sis, trastuzumab has provided clear clinical benefits in
the primary systemic therapy (PST), adjuvant therapy,
and metastatic breast cancer settings [3-5]. However, the
majority of metastatic disease patients who do initially
respond to trastuzumab generally acquire resistance
within 1 year, and 20% of patients who receive trastuzu-
mab in the adjuvant setting relapse. It is therefore neces-
sary to elucidate the mechanisms responsible for
treatment sensitivity and resistance. In vitro studies have
indicated that trastuzumab has multiple mechanisms of
action. Studies have shown that FcγR2A-131 polymor-
phisms impact a patient’s pathological response and can
enhance the anti-tumor activity of trastuzumab, which is
due, at least in part, to ADCC [6]. ADCC has been re-
ported to occur in HER2+ breast cancer patients treated
with trastuzumab. We believe that it may be possible to
predict the efficacy of trastuzumab-based treatment of
HER2+ breast cancer patients if the likelihood of ADCC
can be determined. It is thought that cell–cell contact is
necessary to induce ADCC by trogocytosis, and thus tro-
gocytosis provides a potential mechanism to trace im-
mune–cancer cell contact. We hypothesize that patients
who show a greater degree of trogocytosis will exhibit a
higher degree of ADCC.
Herein, we report that immune effector cells, such as
CD14+ and CD56+ cells, express HER2 via trastuzumab-
mediated trogocytosis. Furthermore, these trogocytosed-
HER2+ immune effector cells show significantly higher
levels of CD107a expression, a marker of target cancer
cell cytotoxicity, compared to non-trogocytosed-HER2
immune effector cells. Importantly, we have found that
in HER2+ breast cancer patients, trogocytosis can occurin the tumor microenvironment (TME) in the absence
of trastuzumab. From this, we have hypothesized that
patients who show a higher degree of HER2 trogocytosis
prior to trastuzumab administration might show a better
response to trastuzumab treatment; trastuzumab target-
ing of HER2+ tumor cells in these patients could be
more effective and result in greater immune cell ADCC.
Notably, we have found that patients who show a high
degree of HER2 expression on tumor-infiltrated immune
cells (by HER2 trogocytosis) demonstrate a significantly
greater probability of achieving a pathological complete
response (pCR) with trastuzumab-based PST. Thus, our
data indicate that HER2 trogocytosis could be a predict-
ive biomarker for the efficacy of trastuzumab-based PST
in HER2+ breast cancer patients.
Methods
Cells
Her2/Neu-positive (HER2+) BT-474 and SK-BR-3 cell
lines and Her2/Neu-negative (HER2−) MCF7 and MDA-
MB-231 cell lines were obtained from the American
Type Culture Collection. SK-BR-3, MDA-MB-231, and
MCF7 cells were all cultured in RPMI 1640 containing
10% FBS, 100 U/mL penicillin, and 100 μg/mL strepto-
mycin (Invitrogen). BT-474 cells were cultured in
DMEM containing 10% FBS, 100 U/mL penicillin, and
100 μg/mL streptomycin. Cell lines were regularly tested
and maintained negative for mycoplasma species. PBMCs
were obtained from patients as part of their routine inves-
tigations at the Kyoto University Hospital. PBMCs were
also obtained from healthy volunteers. Briefly, 8 mL of
blood was collected using a VACUTAINER®CPT™ (Cell
Preparation Tube; BD, Franklin Lakes, NJ). CPTs were
stored at room temperature and processed in accordance
with the manufacturer’s instructions within 6 h to collect
the PBMCs and plasma. CD14+ monocytes and CD56+
NK cells were isolated by depletion (negative selection) of
non-monocyte and non-NK cells, respectively, according
to the manufacturer’s instructions (Pan Monocyte
Isolation Kit (Cat. No. 130-096-537) and NK cell isolation
Kit (Cat. No. 130-092-657), Miltenyi Biotec). The isolated
PBMCs, monocytes, and NK cells were used in assays
immediately.
Tumor dissociation
Immediately after surgical resection, solid breast tumor
samples were minced and dissociated into single-cell
suspensions by incubating at 37°C for 1 h with 1 M
HEPES cell dissociation buffer containing 200 U/mL of
Liberase TM (Roche) in basic accordance with the modi-
fied protocol reported by Panchision et al. [7]. This
method was evaluated and found to yield a cell suspen-
sion with appropriate dissociation efficiency, cell viabil-
ity, and antigen retention for analysis by flow cytometry.
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Isolated PBMCs, monocytes, and NK cells (effector cells)
were co-cultured with different ratios (1:1, 10:1, 100:1,
or 1000:1) of human breast cancer cell lines or breast
cancer patient tumor cells (target cells) in RPMI 1640
alone or in RPMI 1640 containing different concentra-
tions of normal human plasma. Cells were co-cultured
in Eppendorf 500 Tubes® (C153008O, Eppendorf AG,
Hamburg, Germany) for 60 min at 37°C, 5% CO2, in
the presence of different concentrations of trastuzumab
(0, 0.1, and 1 μg/mL; provided by Chugai Pharmaceutical
Co., Ltd.). The optimal time and effector:target (E:T) cell
ratios were determined in preliminary studies (data not
shown). After co-culture, the cells were transferred to
fluorescence-activated cell sorter tubes (Corning, Cat. No.
352235), washed with 0.5% BSA-PBS, and centrifuged at
300 × g for 5 min. The supernatant was discarded and the
cells were re-suspended in 0.5% BSA-PBS and analyzed by
flow cytometry using a FACSCalibur (BD Biosciences).
The expression of HER2 (stained with FITC, PE, or APC-
conjugated anti-HER2 antibodies; BD Biosciences) was de-
termined on target breast cancer cells and on CD14+
(stained with FITC-conjugated anti-CD14 antibodies; BD
Biosciences, Cat. No. 555397), CD56+ (stained with PE-
conjugated anti-CD56 antibodies; BD Biosciences, Cat.
No. 555516), CD19+ (stained with FITC-conjugated anti-
CD19 antibodies; BD Biosciences, Cat. No. 557398), and
CD3+ (stained with PE-conjugated anti-CD3 antibodies;
BD Biosciences, Cat. No. 555340) cells. Antibodies were
diluted 1:20 with Flow Cytometry Staining Buffer (BD
Biosciences, Cat. No. 00-4222-26) prior to staining. Posi-
tive cell populations were gated with reference to negative
isotype control matched antibody staining reactions
(Mouse IgG1 PE and APC, Cat. No. 559320 and 554681,
respectively; Mouse IgG2a FITC, Cat. No. 553456; BD
Biosciences) and baseline HER2 expression on CD14+,
CD56+, CD19+, and CD3+ cells from normal healthy vol-
unteer PBMCs (without cancer cell co-culture). Data were
stored electronically for reanalysis (FlowJo Version 7.6.5
software; TreeStar).
ADCC assay
A mixture of effector and breast cancer cells (E:T ratio = 10:1,
the same ratio as the trogocytosis assay) was prepared
in RPMI 1640 medium and treated with trastuzumab
(0, 0.1, or 1 μg/mL) for 90 min at 37°C, 5% CO2, prior
to performing the CD107a (PE-Cy5-conjugated anti-
CD107a antibody; eBioscience, San Diego, CA) de-
granulation assay.
Staining of tumor specimens
Surgical specimens from HER2+ breast cancer patients
were paraffin embedded and 4 μm sections were cut.
After deparaffinization with xylene, tissue sections wererehydrated and endogenous peroxidase activity was
quenched with 3% hydrogen peroxide for 10 min. After
steaming for 20–30 min using an electric pressure
cooker (SR-P37, Panasonic, Tokyo, Japan), the sections
were blocked with 5% normal goat serum (Abcam), and
incubated with both anti-human CD14 (Diluted in 1:50,
Clone 7, mouse monoclonal; Leica) and anti-HER2
(Ready-to-Use, Clone 4B5, rabbit monoclonal; Roche)
primary antibodies for 1 h. Alexa Fluor 488-conjugated
anti-mouse IgG (diluted in 1:200, ab150117; Abcam) and
Alexa Fluor 594-conjugated anti-rabbit IgG (diluted in
1:200, ab150084; Abcam) secondary antibodies were
used for immunofluorescence staining of CD14 and
HER2, respectively. The secondary antibodies were ap-
plied for 1 h prior to mounting with Fluoroshield
mounting medium with DAPI (Abcam). To evaluate the
correlation between HER2-trogocytosis and a pCR, sec-
tions were stained using MACH2 double stain 2 (Biocare
Medical) for 1 h, followed by Vulcan Fast Red (Biocare
Medical) addition for HER2 staining.
Statistical analysis
Statistical analyses, including the Student’s t test,
Wilcoxon signed-rank test, and Chi-square test were
performed using JMP Pro 11.
Ethical considerations
In accordance with the Declaration of Helsinki, informed
consent was obtained from all breast cancer patients and
healthy volunteers. The study was approved by the insti-
tutional ethics review committee of Kyoto University
Hospital (Protocol G424).
Results
Trogocytosis is specifically observed in HER2+ breast
cancer cell lines and CD14+ cells exhibited a greater
degree of trogocytosis than CD56+ cells in in vitro
trogocytosis assays
Initially, we performed a trogocytosis assay to determine
whether trastuzumab-mediated trogocytosis specifically
occurred in HER2+ breast cancer cells. We used the
HER2+ SK-BR-3 and BT-474 and HER2− MCF7 and
MDA-MB-231 breast cancer cell lines. An E:T cell ratio of
10:1 was used, and 0, 0.1, or 1 μg/mL of trastuzumab (H)
was added for 60 min. The E:T cell suspensions were
stained with FITC-CD14, PE-CD56, and APC-HER2 anti-
bodies and were analyzed by flow cytometry. In the cell
suspensions with HER2+ target cells, both the CD14+ and
CD56+ cells expressed HER2 on their cell surface, indi-
cative of HER2-trogocytosis. The proportion of CD14+
cells that were also HER2+ was significantly higher in
the HER2+ SK-BR-3 and BT-474 cell suspensions
treated with 0.1 and 1 μg/mL of trastuzumab than in
the HER2− MCF7 and MDA-MB-231 cell suspensions
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showed significantly more HER2-trogocytosis than the
CD56+ cells in both the SK-BR-3 and BT-474 cell sus-
pensions (Figure 1A). In order to determine whether
IgG1 antibodies present in normal human plasma affect
HER2 trogocytosis, we performed the trogocytosis
assay in RPMI 1640 medium supplemented with differ-
ent dilutions of normal human plasma (1:2, 1:5, 1:10,
and 1:50). The results indicated that the CD14+ cell
HER2-trogocytosis observed in Figure 1A was abro-
gated in a normal human plasma dose-dependent man-
ner (Figure 1B). We proceeded to investigate whether
effector cells, such as CD19+ B cells and CD3+ T cells,
other than CD14+ monocytes and CD56+ NK cells, also
demonstrated HER2 trogocytosis. However, no increased
HER2 expression was observed on CD19+ or CD3+ cells
in the trogocytosis assay (Additional file 1: Figure S1A).
CD107a is predominantly expressed on CD56+ rather than
CD14+ cells in 90 min ADCC assays
Having shown that normal human plasma potentially
inhibits CD14+ cell HER2-trogocytosis, we eliminatedFigure 1 HER2-trogocytosis and CD107a expression on immune effec
cell lines and HER2− MCF7 and MDA-MB-231 cell lines were used as target cells,
60 min in the trogocytosis assay and 90 min in the CD107a degranulation assay.
antibodies and subjected to flow cytometry. A The trogocytosis assay was perfor
of trastuzumab (H: H0, without trastuzumab; H0.1, 0.1 μg/mL of trastuzumab; H1,
was performed with an E:T cell ratio of 10:1 and 1 μg/mL of trastuzumab
various dilutions (1:50, 1:10, 1:5, and 1:2). The target cancer cells used in t
cytotoxicity (ADCC) assay was performed with an E:T cell ratio of 10:1 and var
CD14+ and CD56+ cell target cancer cell cytotoxicity. *P < 0.05. D CD107a pos
cells is shown. The target cancer cells used in the assay were SK-BR-3. *P
onto CD14+ and CD56+ effector cells. All figures show the mean ± SEM.
and similar data were obtained each time. All figures show the results froplasma from the medium and buffer of further experi-
ments. This was particularly important given that the
clinical relevance and mechanisms of this plasma in-
hibitory effect are not fully understood.
We proceeded to measure the target cell cytotox-
icity of effector cells by quantifying the extracellular
expression of the degranulation marker CD107a on
CD14+ and CD56+ cells. SK-BR-3 and BT-474 cells
were used as target cells and the ADCC assay was
performed as specified in the Methods section.
CD107a expression on CD14+ and CD56+ cells began
to be observed after 60 min in the ADCC assay and
reached a plateau after 90 min. We therefore per-
formed a 90 min ADCC assay to quantify CD107a ex-
pression. Although the mechanism of target cell
killing is different between CD14+ and CD56+ cells,
both the CD14+ and CD56+ cells expressed CD107a
in a trastuzumab dose-dependent manner. When the
level of CD107a expression was analyzed on total
CD14+ or CD56+ cells, CD107a expression was sig-
nificantly greater on CD56+ cells than on CD14+ cells
(Figure 1C).tor cells in human breast cancer cell lines. HER2+ SK-BR-3 and BT-474
and healthy human PBMCs were used as effectors. Cells were co-cultured for
Cells were stained with FITC-CD14, PE-CD56, APC-HER2, and PE-Cy5-CD107a
med with an effector:target (E:T) cell ratio of 10:1 and various concentrations
1 μg/mL of trastuzumab). *P < 0.05; **P < 0.001. B The trogocytosis assay
(H1). Normal human plasma was added to the co-culture medium at
he assay were SK-BR-3. *P < 0.05. C The antibody-dependent cellular
ious concentrations of trastuzumab (H). CD107a positivity is indicative of
itivity on HER2+/CD14+, HER2−/CD14+, HER2+/CD56+, and HER2−/CD56+
< 0.05; **P < 0.001. HER2 positivity represents the uptake of HER2
Experiments were performed for 3 healthy volunteers at least 2 times
m a single representative experiment.
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trogocytosis) express significantly higher levels of
CD107a
To confirm the role of trogocytosis in ADCC, the level
of CD107a expression on trogocytosed-HER2+/CD14+
and trogocytosed-HER2+/CD56+ cells was compared
to CD107a expression on non-HER2-trogocytosed
HER2−/CD14+ and HER2−/CD56+ cells. Using flow cy-
tometry, it was shown that CD107a expression was
significantly higher on the trogocytosed-HER2+/CD14+
and trogocytosed-HER2+/CD56+ cells than the non-
HER2-trogocytosed immune effector cells (Figure 1D).
Representative dot plots are shown in Additional file 1:
Figure S1B.Figure 2 Reduction in HER2 expression in HER2+ target human breas
CD56+ immune cells in the absence of trastuzumab. SK-BR-3 and BT-47
For the trogocytosis assay, cells were co-cultured for 60 min. Cell mixtures we
flow cytometry. A The trogocytosis assay was performed with an E:T cell ra
trastuzumab; H0.1, 0.1 μg/mL of trastuzumab; H1, 1 μg/mL of trastuzuma
of trastuzumab alone, respectively. B The trogocytosis assay was perform
trastuzumab. C The trogocytosis assay was performed with an E:T cell ratio of 1
***P < 0.001 versus cancer cells only. D The trogocytosis assay was performed w
cells and without trastuzumab (H0). The level of HER2 expression on the CD14
condition. *P < 0.05; **P < 0.001. All figures show the mean ± SEM. Experimen
were obtained each time.Trogocytosis reduces HER2 expression on HER2+ target
cancer cells and HER2 expression on isolated CD14+ and
CD56+ immune cells in the absence of trastuzumab was
also shown
The results from the trogocytosis assay indicated that
HER2 expression on target cancer cells was reduced as
the trastuzumab dose increased (Figure 2A). However,
HER2 expression in SK-BR-3 and BT-474 cells does not
decrease when they were incubated with trastuzumab
alone for 60 min (Figure 2A: SK-H1 and BT-H1, respect-
ively). This result suggests that 60 min is insufficient for
direct internalization of the HER2-trastuzumab complex,
and that trogocytosis is the key mechanism responsible
for the loss of HER2 in the 60 min trogocytosis assay.t cancer cell lines and HER2 expression on isolated CD14+ and
4 were used as targets and healthy human PBMCs were used as effectors.
re subsequently stained with an APC-HER2 antibody and subjected to
tio of 10:1 and various concentrations of trastuzumab (H: H0, without
b). SK-H1 and BT-H1; SK-BR-3 and BT-474 cells treated with 1 μg/mL
ed with an E:T cell ratio of 10:1, 100:1, and 1000:1 and 1 μg/mL of
0:1, 100:1, and 1000:1 without trastuzumab treatment. *P < 0.05; **P < 0.01;
ith isolated CD14+ or CD56+ cells in 1:2, 1:1 and 2:1 ratio with SK-BR-3
+ and CD56+ cells is shown as the percent of HER2+ cells in each
ts were performed for a single healthy volunteer twice and similar data
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greater decrease in HER2 expression was observed in
both the trastuzumab-dependent (TD; Figure 2B) and
trastuzumab-independent (TI; Figure 2C) trogocytosis
assays. To confirm that the uptake of HER2 onto CD14+
and CD56+ effector cells in TI trogocytosis, we assayed
TI trogocytosis using purified CD14+ and CD56+ cells
with E:T cell ratios of 1:2, 1:1 and 2:1. Although the pre-
cise mechanisms of TI HER2-trogocytosis are not clear,
by performing trogocytosis assays in trastuzumab-free
conditions, we found that CD14+ and CD56+ cells in
CD14+ and CD56+ cells purified from PBMCs (91.5%
and 96.9% purity, respectively; data not shown) express
HER2 on the cell surface by trogocytosis. As the T:E cellFigure 3 ADCC and trogocytosis in PBMCs from HER2+ breast cancer
cells in all experiments and PBMCs from HER2+ breast cancer patients (N =
SK-BR-3 cells and PBMCs were co-cultured for 60 min in the trogocytosis a
the assays were stained with FITC-CD14, PE-CD56, APC-HER2, and PE-Cy5-C
assay was performed with an E:T cell ratio of 10:1 with and without trastuz
positivity represents the uptake of HER2 onto CD14+ and CD56+ effector ce
and without trastuzumab (H0, without trastuzumab; H1, 1 μg/mL of trastuz
by CD14+ and CD56+ cells. C CD107a positivity on HER2+/CD14+, HER2−/CD1
assay was performed with an E:T cell ratio of 10:1 with and without trastuzum
HER2 expression on the trogocytosed SK-BR-3 cells is shown as the percen
show the mean ± SD. Healthy volunteers are represented by open circles, squ
and triangles.ratio increased, the quantity of HER2 on the surface of
isolated CD14+ cells and CD56+ cells also increased
(Figure 2D).
Patient PBMCs exhibit HER2-trogocytosis although the
extent is variable
To investigate the clinical significance of our findings,
we examined the trogocytosis potential of freshly iso-
lated PBMCs from early stage HER2+ breast cancer pa-
tients. Similar to the PBMCs of healthy volunteers, both
the CD14+ and CD56+ immune effector cells in the
PBMCs of breast cancer patients’ showed HER2-
trogocytosis (Figure 3A) and target cell cytotoxicity
(Figure 3B). Furthermore, the trogocytosed-HER2+/CD14+patients and healthy volunteers. SK-BR-3 cells were used as target
3) and healthy volunteers (N = 3) were used as effector cells. The
ssay and 90 min in the CD107a degranulation assay. Cell mixtures from
D107a antibodies and subjected to flow cytometry. A The trogocytosis
umab (H0, without trastuzumab; H1, 1 μg/mL of trastuzumab). HER2
lls. B The ADCC assay was performed with an E:T cell ratio of 10:1 with
umab). CD107a positivity is indicative of target cancer cell cytotoxicity
4+, HER2+/CD56+, and HER2−/CD56+ cells is shown. D The trogocytosis
ab (H0, without trastuzumab; H1, 1 μg/mL of trastuzumab). The level of
t of HER2+ cells in each condition. *P < 0.005, **P < 0.05. All figures
ares, and triangles; patients are represented by closed circles, squares,
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significantly higher CD107a expression (Figure 3C). A
reciprocal reduction in HER2 expression on the HER2
+ cancer cells was also observed in the patient’s cells
(Figure 3D). However, there was also a large variation
in the degree of trogocytosis and the extent of HER2
reduction among patients and healthy volunteers. Al-
though the increased HER2 expression on CD14+ or
CD56+ cells was not robustly correlated with reduced
HER2 cancer cell expression, the diversity in response
suggests that trogocytosis has the potential to be used
as a predictive marker for trastuzumab-based treat-
ment efficacy in breast cancer patients.Flow cytometry of HER2+ breast cancer patient’s tumor
cells indicates high HER2 expression on CD14+ and CD56+
cells
In order to confirm that HER2 was expressed on tumor-
infiltrated immune cells, and determine whether HER2
could be transferred to immune effector cells by trogo-
cytosis, we isolated individual tumor cells from a HER2+
breast cancer patient treated with trastuzumab (N = 1)
and a HER2− luminal type breast cancer patient. Dissoci-
ated tumor tissue cell suspensions were subjected to
flow cytometry and forward/side scatter, CD14, and
CD56 staining was used to distinguish the cancer cell,
monocyte, and lymphocyte populations. Cancer cells and
monocytes were of a similar size but monocytes were
CD14+ (Additional file 2: Figure S2; cancer cells indi-
cated by red circle and monocytes indicated by yellow
circle). Lymphocytes were smaller than cancer cells and
monocytes and appeared as a distinct cell population
(Additional file 2: Figure S2; indicated by blue circle).
Interestingly, flow cytometry indicated that HER2 ex-
pression was higher on the patient’s tumor-infiltrated
CD14+ cells than the CD14+ PBMCs (19.3% and 1.29%,
respectively; Additional file 2: Figure S2A). As a negative
control, we also tested HER2 expression on the CD14+
cells of a HER2− luminal type breast cancer patient; no
HER2 expression was observed on the CD14+ cells of
the luminal type breast cancer patient (Additional file 2:
Figure S2A; luminal type tumor). The CD56+ NK cells
from tumors were identified by CD56+ staining in the
lymphocyte population (identified through their for-
ward/side scatter properties), which had previously
been identified as being smaller than the cancer cells
and monocytes (red and green circles, respectively;
Additional file 2: Figure S2B). Similar to the CD14+ im-
mune effector cells, the tumor-infiltrated CD56+ cells
from HER2+ breast cancer patients expressed high
levels of HER2 and the CD56+ cells from luminal type
breast cancer patient showed little HER2 expression
(Additional file 1: Figure S2B).HER2 can be transferred from tumor cells to CD14+ and
CD56+ immune cells by autologous trogocytosis
A single autologous trogocytosis assay was performed by
co-culturing digested tumor cell suspensions and
PBMCs from the HER2+ patient at a ratio of 1:10 with
either 0 or 1 μg/mL of trastuzumab. The number of
HER2+/CD14+ and HER2+/CD56+ cells was higher in
the co-culture treated with 1 μg/mL of trastuzumab than
in the untreated co-culture (Additional file 3: Figure
S3A, CD56+ and CD14+ cells). Furthermore, HER2 ex-
pression on digested tumor cells was lower in co-
cultures treated with 1 μg/mL of trastuzumab than in
cultures treated with 0 μg/mL of trastuzumab (18% and
25%, respectively; Additional file 3: Figure S3A, Tumor
cell). Although direct HER2 internalization by trastuzu-
mab is one possible mechanism of down-modulation of
HER2, these findings suggest that HER2 can be transferred
from HER2+ breast tumor cells to CD14+ and CD56+
cells, which provides potential evidence for trogocytosis
within the TME of HER2+ breast cancer patients.
Confirmation of TI trogocytosis using autologous
trogocytosis assays
To investigate the potential for TI trogocytosis, digested
tumor cell suspensions and autologous PBMCs from the
HER2+ patient were co-cultured in various ratios with-
out trastuzumab; HER2 expression reduced as the E:T
cell ratio increased (Additional file 3: Figure S3B). This
suggests that cancer cell–immune cell contact occurs in
the absence of a HER2-targeting antibody, and this could
also occur in the TME of HER2+ breast cancer patients.
Such contact could result in immune cells that express
trogocytosed-HER2 after encountering HER2 expressing
cancer cells. This is clinically significant because it may
enable the efficacy of trastuzumab-based treatment to be
predicted in individual HER2+ breast cancer patients by
evaluating the probability of immunological HER2-
trogocytosis.
Tumor-infiltrated immune cell HER2 expression may be
associated with a pCR
To investigate whether HER2-trogocytosis prior to treat-
ment could be used to predict HER2+ breast cancer pa-
tients’ responses to PST consisting of anthracyclin
followed by taxan plus trastuzumab, we evaluated HER2
trogocytosis in formalin-fixed paraffin embedded tumor
samples collected from patients at Kyoto University
Hospital from 2008 to 2012 (N = 13; 7 pCR and 6 non-pCR
patients were included). The patient’s clinicopathological in-
formation is shown in Table 1. HER2+ tumor-infiltrated im-
mune cells (trogocytosed-HER2+ immune cells) were
analyzed by immunohistochemical staining, which was
interpreted by an expert pathologist who was blind to pa-
tient information. The absolute number of trogocytosed-











07-9749 FEC→ PH non pCR 0 0 3+ NA
08-9679 FEC→ PH non pCR 100 80 3+ 30
09-3788 FEC→ PH pCR 0 0 3+ 10
09-5807 FEC→ PH pCR 80 30 3+ 30
10-248 FEC→ DH pCR 60 70 3+ 25
10-7977 FEC→ PH non pCR 30 0 3+ 20
10-8712 FEC→ PH pCR 0 1 3+ 40
11-577 FEC→ PH non pCR 5 0 3+ 30
11-5192 FEC→ PH non pCR 10 30 3+ 80
11-10011 FEC→ PH pCR 100 40 3+ 22
12-2401 FEC→ PH pCR 10 0 3+ 39.6
10-09897 FEC→ PH pCR 0 0 3+ 25
10-06979 FEC→ PH non pCR 0 0 3+ 10
FEC, 5-fluorouracil epirubicin cyclophosphamide; P, paclitaxel; D, docetaxel;
H, trastuzumab.
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counted; the median was 11. We defined a highly trogocy-
tosed tumor as one in which 12 or more trogocytosed-
HER2+ immune cells were present and a lowly trogocytosed
tumor as one in which fewer than 11 trogocytosed-HER2+
immune cells were present. Representative immunofluores-
cence and immunohistochemical staining of HER2+ tumor-
infiltrated immune cells in HER2+ breast cancer tissues are
shown in Figures 4A and B. The correlation between
trogocytosed-HER2+ immune cells and patient response
was analyzed; we found that patients with a high degree of
HER2-trogocytosis had a significantly greater probability
of achieving a pCR with PST consisting of 3–4 courses of
FEC100 followed by 12 courses of paclitaxel and trastuzu-
mab than patients with a low level of HER2-trogocytosis
(P = 0.023; Figure 4C).
Discussion
In vitro trastuzumab-mediated trogocytosis has been ex-
tensively investigated by Beum et al., who have shown
that trogocytosis of monoclonal antibody (trastuzumab,
rituximab, or cetuximab)-opsonized cells is mediated by
PBMC, THP-1, and primary monocytes. It is likely that
these monoclonal antibodies, and potentially other anti-
cancer monoclonal antibodies now used in the clinic, also
promote trogocytic removal of the therapeutic antibody
and their cognate antigens from tumor cells in vivo [1]. In
the present study, we aimed to demonstrate the existence
and clinical significance of HER2+ tumor-infiltrated im-
mune cells in HER2+ breast cancer patients receiving tras-
tuzumab treatment. To the best of our knowledge, this is
the first study to report potential evidence for HER2 trans-
fer from HER2+ breast cancer cells to immune cells,including CD14+ and CD56+ cells, by trogocytosis in
HER2+ breast cancer patients (Additional file 2: Figure S2
and Figure 4). Moreover, the presented findings could pro-
vide a novel strategy, beyond the conventional evalu-
ation of HER2 expression, for predicting the patients
who are most likely to achieve a pCR with preoperative
trastuzumab-based systemic therapy; it may be possible to
identify patients who are likely to achieve a pCR by evaluat-
ing the status of HER2 expression on tumor-infiltrated im-
mune cells (Figure 4). Importantly, as shown in Figure 1B,
CD14+ cell HER2-trogocytosis was abrogated in the pres-
ence of normal human plasma. Herceptin is an IgG1 kappa
light chain antibody. Human serum/plasma contains a high
concentration of IgG1 kappa light chain antibodies.
PBMCs, which were used in the in vitro trogocytosis assays,
can bind to IgG1 antibodies, such as trastuzumab or those
stemming from human serum/plasma. As such, it is pos-
sible that trastuzumab and human serum/plasma IgG1
antibodies may compete with one another in vivo for bind-
ing to immune cell receptors, which could account for the
inconsistent in vitro results. However, the clinical relevancy
and precise mechanisms of this action remain unclear and
the future experimental and clinical studies are required.
In order to confirm whether trogocytosis is caused by
trastuzumab in HER2+ breast cancer patients, it would
be necessary to compare the levels of HER2 expression
on tumor-infiltrated immune cells before and after tras-
tuzumab treatment. However, practically, it is difficult to
analyze fresh tumor samples by flow cytometry prior to
cancer diagnosis and identification of the biological
phenotype, for example, the ER or HER2 status. As
shown in Additional file 2: Figure S2, a significant in-
crease in HER2 expression on tumor-infiltrated CD14+
and CD56+ cells was observed after administration of
the anti-HER2 antibody trastuzumab to HER2+ breast
cancer patients. Although it cannot be definitively con-
cluded that HER2 was transferred from the cancer cells
to the CD14+ and CD56+ cells by trogocytosis, the ob-
servation is significant because HER2 expression is not
usually observed on CD14+ and CD56+ cells in normal
PBMCs (Additional file 2: Figures S2A and B). Support-
ing the notion that HER2 trogocytosis is specific to
HER2+ breast cancer, only low levels of HER2 expres-
sion were observed on the CD14+ and CD56+ cells of
luminal type tumors (Additional file 2: Figures S2A and
B; luminal type tumor). Moreover, a trastuzumab
concentration-dependent attenuation of target cancer
cell HER2 expression (although direct HER2 internaliza-
tion by trastuzumab is one possible mechanism of
down-modulation of HER2), and reciprocal increase in
CD14+ and CD56+ immune cell HER2 expression, was
observed in the HER2+ patient tumor cell–autologous
PBMC trogocytosis assay (Additional file 3: Figure S3A).
Although we had previously thought that trogocytosis
Figure 4 HER2 expression on the tumor infiltrated immune cells of HER2+ breast cancer patients. A Representative immunofluorescence
staining of CD14+/HER2+ cells (HER2-trogocytosis) in HER2+ breast cancer tissues. Green arrow, CD14+ cells; red arrow, HER2+ cells; white arrow,
CD14+/HER2+ cells. B Representative immunohistochemical staining of HER2 in HER2+ breast cancer tissues before systemic treatment. Black
arrows indicate HER2+ tumor infiltrated immune cells. C Correlation between HER2-trogocytosis and a pathological complete response (pCR) in
13 HER2+ breast cancer patients treated with trastuzumab-based primary systemic therapy (P < 0.05).
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autologous transfer of HER2 from cancer cells to CD14+
and CD56+ cells might occur. Ross et al. have investi-
gated trogocytosis in both the allogeneic experimental
setting and in patients with multiple myeloma and other
B-cell malignancies; they identified 2 molecules as po-
tential transfer candidates, human leukocyte antigen
(HLA)-G and the B7 molecule CD86, and identified T
cells as the most common recipient lymphocyte subpop-
ulation [8]. It was this evidence that encouraged us to
conduct trogocytosis studies using human breast cancer
cell lines and human PBMCs, even though these were
only allogeneic-type experiments.
The question of whether HER2 expression on CD14+
monocytes following trogocytosis is effective at provid-
ing an acquired immune response against HER2+ breast
cancer cells is an important one. The molecular pheno-
type of HER2 expression on CD14+ monocytes has not
been clearly investigated and, as such, our understandingof the extent and clinical significance of this trogocytosis
is still very limited [9-14]. However, there are several
reports that suggest that trogocytosis might act to sti-
mulate immunological tolerance or immune effector
cell activation [8,15-18]. We performed trastuzumab-
dependent (TD) and trastuzumab-independent (TI) tro-
gocytosis assays using PBMCs from healthy volunteers
and HER2+ breast cancer patients as effector cells and
HER2+ breast cancer cell lines as the target cells. We
found that the CD14+ immune effector cell subset
showed greater TD HER2 trogocytosis than the CD56+
cells (Figures 1A and 3A). In addition, CD56+ cells
showed greater CD107a expression than the CD14+ cells
(Figures 1C and 3B). Little or no HER2 expression was
observed on the CD14+ and CD56+ PBMCs of the
healthy volunteers and HER2− breast cancer patient;
similarly, little or no HER2 expression was observed on
the tumor-infiltrated CD14+ and CD56+ PBMCs of the
HER2− breast cancer patient. Thus, we believe that
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of contact between immune cells and HER2+ cancer
cells. Tight cancer–immune cell contact is critical for
target cancer cell destruction by immune effector cells
[19] and, as such, the trogocytosed-HER2+ immune cells
should exhibit effective trastuzumab-mediated target
cancer cell ADCC. Indeed, the trogocytosed-HER2+ im-
mune effector cells showed higher levels of CD107a ex-
pression than the non-HER2-trogocytosed immune
effector cells (Figures 1D and 3C). We therefore con-
clude from the current study that HER2 trogocytosis is
proof of target cancer cell elimination by ADCC.
In this study, TI and TD HER2 trogocytosis by im-
mune effector cells was shown to result in a reduction in
HER2 expression on target HER2+ breast cancer cells
(Figure 2A-C). This finding indicates a possible role for
HER2 trogocytosis in modulating HER2 expression on
HER2+ breast cancer cells. However, most studies to
date have indicated that loss of the HER2 extracellular
domain (ECD) is principally caused by shedding of the
HER2 ECD or direct internalization of the trastuzumab-
HER2 complex. Despite lacking the majority of the ECD,
truncated HER2 receptors have been shown to be cap-
able of stimulating breast cancer progression in vivo and
in clinical studies of breast cancer patients [20,21].
HER2 shedding plays an important role in trastuzumab
treatment response and resistance. However, the inter-
action of immune cells with HER2+ trastuzumab-
opsonized cancer cells in the TME is also a crucial factor
in trastuzumab treatment response. We believe that
TME HER2 trogocytosis by immune effector cells is an
important mechanism of HER2 reduction, which could
potentially affect trastuzumab treatment outcome. The
trogosytosis assays, shown in Figure 2, indicate that
HER2 expression on target cancer cells was down-
regulated in both SK-BR-3 and BT-474 cells. Previous
western blotting studies of cell lysates have indicated
that full-sized transmembrane major histocompatibility
complex (MHC) class I protein and cognate NK-cell re-
ceptor exchange can occur between cells, and that intact
MHC class I protein can be transferred from antigen
presenting cells to T cells [9]; this indicates that trogocy-
tosis does not involve proteolytic cleavage. Furthermore,
trogocytosed proteins can commonly be detected by
monoclonal antibodies targeted against both extracellu-
lar epitopes and intracellular fluorescent protein tags,
further indicating that both the intracellular and extra-
cellular epitopes of transmembrane proteins are trans-
ferred [22,23]. This leads us to speculate that the full
sized HER2, including the ECD and intracellular phos-
phorylation domain, is transferred during HER2-
trogocytosis. This is distinct from proteolytic shedding
of HER2, and consequently, we believe that HER2 trogo-
cytosis may inhibit HER2 intracellular signal transduction,which could induce target cancer cell death. We therefore
further hypothesize that TD HER2 trogocytosis, which re-
sults in reduced target cancer cell HER2 expression, could
induce target cancer cell death by pro-apoptotic proteins,
such as granzymes and TNF-alpha, in addition to inducing
trastuzumab-mediated ADCC. As such, increased trogo-
cytosis induction may be associated with improved trastu-
zumab treatment efficacy.
From the presented results, we believe that the TI
HER2 trogocytosis results are of the greatest clinical sig-
nificance. Patients who exhibited a greater degree of TI
HER2 trogocytosis achieved a greater degree of HER2
trogocytosis following HER2+ breast cancer cell target-
ing by trastuzumab, resulting in these patients experien-
cing more trastuzumab-mediated ADCC. Although the
mechanism through which this occurs is not fully appre-
ciated, host immune cell factors and cancer cell charac-
teristics could play a role. Although efforts were made to
stain the CD14+ and CD56+ tumor infiltrated immune
cells, satisfactory staining was not achieved (most likely
due to the use of inappropriate antibodies). Salgado
et al. of the Tumor Infiltrating Lymphocytes Working
Group recently recommended that immunohistochemis-
try is not used to detect specific cellular subpopulations
in clinical evaluation settings [24]. Therefore, we chose
to determine the level of TI HER2 trogocytosis by evalu-
ating the status of HER2 expression on tumor-infiltrated
immune cells from HER2+ breast cancer patients who
were due to be treated with trastuzumab-based PST.
The patients were divided into 2 groups depending on
the degree of trogocytosed-HER2+ tumor-infiltrated im-
mune cells (Figure 4B); the patients who showed a high
degree of HER2 expression on tumor-infiltrated immune
cells (by TI HER2 trogocytosis) demonstrated a signifi-
cantly greater probability of achieving a pCR with
trastuzumab-based PST (Figure 4C). Previous studies
have indicated that increased levels of tumor-infiltrated
lymphocytes could be a predictive factor for PST re-
sponse [25,26]. However, we identified 2 cases in which
there was a high level of tumor-infiltrated lymphocytes,
but low trogocytosis; neither of these patients achieved a
pCR. As such, we believe the clinical application of our re-
sults could result in a more accurate prediction of HER2+
breast cancer patient’s response to PST (Figure 4B). Fol-
lowing the publication of a recent report which indicated
that high HER2 protein and high HER2 and HER3 mRNA
levels correlate with a better response to anti-HER2 anti-
body based treatment [27], it has been suggested that a
high level of HER2 expression is necessary to achieve a
good response to anti-HER2 therapy. Therefore, in consid-
ering the clinical importance of low HER2-trogocytosis,
we suggest that HER2+ breast cancer patients whose
tumor HER2 immunohistochemistry score is 3+ or 2+
might actually have a low quantity of HER2 protein.
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protein may exhibit a poor response to anti-HER2 anti-
body treatment due to low levels of HER2-trogocytosis in
addition the effect that low levels of HER2 protein have on
anti-HER2 therapy response. However, given the low
number of patient samples in the current study, a larger
patient population study is required in order to determine
the true clinical significance of HER2-trogocytosis.
Conclusions
TME interactions between immune cells, trastuzumab,
and cancer cells are important when considering the
anti-HER2 antibody treatment of HER2+ breast cancer
patients. We have shown that immune cell trogocytosis
prior to trastuzumab treatment may correlate with
achieving a pCR with trastuzumab-based PST. Further
evaluation is required to establish whether the response
to HER2-targeted antibody therapy in HER2+ breast
cancer patients can be determined by trogocytosis ana-
lysis, but we believe that future translational research to
evaluate the clinical impact of trogocytosis in a cohort of
anti-HER2 treatment trials is warranted.
Additional files
Additional file 1: Figure S1A-B. There was no significant increase in
HER2 expression on CD3+ or CD19+ cells in trogocytosis assays. The
trogocytosis assay was performed with an E:T cell ratio of 10:1 and
various concentrations of trastuzumab (H: H0, without trastuzumab; H1,
1 μg/mL of trastuzumab). HER2 positivity represents the uptake of
HER2 onto CD14+, CD56+, CD3+, and CD19+ effector cells. Figure
S1B. HER2+/CD14+ cells and HER2+/CD56+ cells have greater
CD107a expression. Representative flow cytometry scatterplots of
CD107a expression on HER2+/CD14+ vs HER2−/CD14+ and HER2
+/CD56+ vs HER2−/CD56+ cells are shown.
Additional file 2: Figure S2. Expression of HER2 on tumor-infiltrated
CD14+ and CD56+ cells in a HER2+ breast cancer patient treated with
trastuzumab. Tumors from a trastuzumab treated HER2+ breast cancer
patient and a HER2− luminal type breast cancer patient were enzymatically
dissociated to obtain cell suspensions which were subjected to flow
cytometry in parallel with the patient’s PBMCs. The cells were stained with
FITC-CD14, PE-CD56, and APC-HER2 antibodies. A CD14+ cells in patient
PBMCs were gated against HER2 expression (APC; top 2 panels). CD14+ cells
from dissociated tumors (bottom left panel, yellow circle) were gated
against HER2 expression (APC) in both HER2+ and luminal type tumors
(bottom right 2 panels). B CD56+ cells in patient PBMCs were gated against
HER2 expression (APC; top 2 panels). CD56+ cells from dissociated tumors
(bottom left panel, yellow circle) were gated against HER2 expression (APC)
in both HER2+ and luminal type tumors (bottom right 2 panels).
Additional file 3: Figure S3. Trastuzumab-mediated trogocytosis in
autologous tumor cells and PBMCs from a HER2+ breast cancer patient.
The tumor sample from the trastuzumab-untreated HER2+ breast cancer
patient was enzymatically dissociated and the obtained cell suspension
and patient’s autologous PBMCs were subjected to a trogocytosis assay
(E:T cell ratio = 10:1; H0, without trastuzumab; H1, trastuzumab 1 μg/mL).
A The expression of HER2 on CD56+, CD14+, and tumor cells in H0 and
H1 treated samples is shown. In the CD56+ and CD14+ cell plots, the solid
line represents HER2 staining and the dashed line represents isotype control
staining. B Trastuzumab independent (TI) trogocytosis in autologous tumor
cells and PBMCs. The TI trogocytosis assay was performed using dissociated
HER2+ tumor cells and the patient’s autologous PBMCs with an E:T cell ratio
of 1:1, 10:1, 100:1, and 1000:1 without trastuzumab treatment. The level ofHER2 expression in the trogocytosed cells is shown as the percent of HER2+
cells in each condition. The figures show results from a single patient
experiment.
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